---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000056"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-09-28T12:01:07+00:00"
generated_at: "2026-10-12T13:30:42.270522+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Keros doses first patient in Phase 2 rinvatercept trial in DMD; initial data expected in H1 2027

## Summary
- First patient dosed in open-label, multi-cohort Phase 2 basket trial (NCT07704099) of rinvatercept in late-ambulatory and early non-ambulatory Duchenne muscular dystrophy patients.
- Primary objective is safety and tolerability; key secondary objectives include pharmacokinetics, anti-drug antibodies, body composition and skeletal muscle, motor, cardiac and pulmonary function.
- Company expects initial data from the trial in the first half of 2027.
- CEO Jasbir Seehra said rinvatercept is designed to modulate key regulators of muscle and bone biology, advancing Keros' neuromuscular strategy.
- Gina O'Grady of Starship Children's Hospital said DMD still places a significant burden on patients and the need for additional options remains high.

## SEC filing metadata
- accession: 0001664710-26-000056
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-09-28T12:01:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/0001664710-26-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/kros-20260928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000056
- JSON: https://secwatch.observer/filing/0001664710-26-000056.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.